{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:15:45Z","timestamp":1781478945627,"version":"3.54.1"},"reference-count":150,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1053\/j.seminhematol.2025.12.002","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T23:50:50Z","timestamp":1766447450000},"page":"255-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["T-cell engaging antibodies for B-cell lymphomas"],"prefix":"10.1053","volume":"62","author":[{"given":"Dong Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.seminhematol.2025.12.002_bib0001","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","author":"K\u00fcppers","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.12.002_bib0002","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/17474086.2017.1318053","article-title":"Lymphoma classification update: B-cell non-hodgkin lymphomas","volume":"10","author":"Jiang","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0003","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Therap Adv Hematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.12.002_bib0005","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.2023023419","article-title":"CAR T cells vs bispecific antibody as third-or later-line large B-cell lymphoma therapy: a meta-analysis","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.12.002_bib0006","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/jpm11050355","article-title":"Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas","volume":"11","author":"Salvaris","year":"2021","journal-title":"J Personalized Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.12.002_bib0007","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0008","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5891","key":"10.1053\/j.seminhematol.2025.12.002_bib0009","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell\u2013engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.12.002_bib0010","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.12.002_bib0011","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.12.002_bib0012","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable responses with mosunetuzumab in relapsed\/refractory indolent and aggressive B-cell non-hodgkin lymphomas: extended follow-up of a phase I\/II study","volume":"42","author":"Budde","year":"2024","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1053\/j.seminhematol.2025.12.002_bib0013","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10306","key":"10.1053\/j.seminhematol.2025.12.002_bib0014","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.12.002_bib0015","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7 CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.12.002_bib0016","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0017","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","article-title":"Fc\u03b3 receptors and immunomodulatory antibodies in cancer","volume":"24","author":"Galvez-Cancino","year":"2024","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.12.002_bib0018","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.12.002_bib0019","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.12.002_bib0020","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nbt.2621","article-title":"Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies","volume":"31","author":"Spiess","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0021","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/jmbi.1997.1116","article-title":"Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library","volume":"270","author":"Atwell","year":"1997","journal-title":"J Mol Biol"},{"issue":"287","key":"10.1053\/j.seminhematol.2025.12.002_bib0022","doi-asserted-by":"crossref","first-page":"287ra70-","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell\u2013dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.12.002_bib0023","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-022-01749-5","article-title":"Mosunetuzumab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.12.002_bib0024","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.12.002_bib0025","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1080\/19420862.2016.1197457","article-title":"The use of crossmab technology for the generation of bi-and multispecific antibodies","volume":"8","author":"Klein","year":"2016","journal-title":"MAbs"},{"issue":"27","key":"10.1053\/j.seminhematol.2025.12.002_bib0026","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc Natl Acad Sci"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.12.002_bib0027","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.12.002_bib0028","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"New Engl J Med"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.12.002_bib0029","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.12.002_bib0031","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.12.002_bib0032","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.12.002_bib0033","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/blood.2025029909","article-title":"Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma","volume":"146","author":"Falchi","year":"2025","journal-title":"Blood J"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0034","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Scient Rep"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.12.002_bib0035","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/bit.20729","article-title":"Antibody variable region interactions with Protein A: implications for the development of generic purification processes","volume":"92","author":"Ghose","year":"2005","journal-title":"Biotechnol Bioengineer"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0036","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.12.002_bib0037","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial","volume":"6","author":"Kim","year":"2025","journal-title":"Nat Cancer"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.12.002_bib0038","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"sup1","key":"10.1053\/j.seminhematol.2025.12.002_bib0039","first-page":"5","article-title":"Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia","volume":"5","author":"Portell","year":"2013","journal-title":"Clin Pharmacol: Adv Applicat"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.12.002_bib0040","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol Therap"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.12.002_bib0041","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.12.002_bib0042","first-page":"1410","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood, J Am Soc Hematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.12.002_bib0043","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-hodgkin lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leukemia Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0044","article-title":"TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL","volume":"13","author":"HK","year":"2021","journal-title":"MAbs"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.12.002_bib0045","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","article-title":"Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies","volume":"11","author":"Trinklein","year":"2019","journal-title":"MAbs"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0046","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2023-174668","volume":"142","author":"Gaballa","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.12.002_bib0047","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10147-024-02662-5","article-title":"Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed\/refractory follicular lymphoma: FLMOON-1","volume":"30","author":"Goto","year":"2025","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.12.002_bib0048","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after\u2265 2 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.12.002_bib0049","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/ejh.14401","article-title":"Relapsed\/refractory follicular lymphoma: current advances and emerging perspectives","volume":"114","author":"Carid\u00e0","year":"2025","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2021-145694","article-title":"Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed\/refractory follicular lymphoma: initial results from a phase ib study","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2025.12.002_bib0051","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/01.HS9.0000847368.92731.fb","article-title":"P1125: CELESTIMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma","volume":"6","author":"Nastoupil","year":"2022","journal-title":"Hemasphere"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0052","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2023-180092","article-title":"EPCORE FL-1: phase 3 trial of subcutaneous epcoritamab with rituximab and lenalidomide (R 2) vs R 2 alone in patients with relapsed or refractory follicular lymphoma","volume":"142","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0053","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-201305","article-title":"Mosunetuzumab and Zanubrutinib in relapsed\/refractory follicular lymphoma patients (MOZART): a phase II, chemo-free trial from Fondazione Italiana Linfomi (FIL)","volume":"144","author":"Ladetto","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0054","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1182\/blood-2023-177917","article-title":"Subcutaneous mosunetuzumab is active and has a manageable safety profile in patients with previously untreated, low-tumor burden follicular lymphoma: initial results from the phase II Morningsun study","volume":"142","author":"Flinn","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0055","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1182\/blood-2024-202085","article-title":"Mosunetuzumab plus polatuzumab vedotin induces early complete responses in previously untreated high tumor burden follicular lymphoma","volume":"144","author":"Russler-Germain","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0056","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2024-200369","article-title":"Fixed-duration Epcoritamab in combination with Bendamustine+ Rituximab for first-line treatment of follicular lymphoma: initial results from Epcore NHL-2 arm 3","volume":"144","author":"Brody","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0057","doi-asserted-by":"crossref","unstructured":"Birhiray RE, Luminari S, Kim TM, et al. Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator\u2019s choice in previously untreated follicular lymphoma (OLYMPIA-1). J Clin Oncol 42, TPS7096(2024), Vol 42, Number 16 suppl. doi:10.1200\/JCO.2024.42.16_suppl.TPS7096.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7096"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0058","doi-asserted-by":"crossref","unstructured":"Hardin C, Gray C, Novelli S, et al. Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2). J Clin Oncol 42, TPS7099(2024), Vol 42, Number 16 suppl. doi:10.1200\/JCO.2024.42.16_suppl.TPS7099.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7099"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0059","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood-2024-193589","article-title":"Escalating doses of AZD0486, a novel CD19xCD3 T-cell engager, result in high complete remissions with rapid clearance of minimal residual disease in patients with relapsed\/refractory follicular lymphoma","volume":"144","author":"Hou","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.12.002_bib0060","first-page":"1483","article-title":"New bispecific antibodies in diffuse large B-cell lymphoma","volume":"110","author":"Minson","year":"2025","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.12.002_bib0061","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0062","doi-asserted-by":"crossref","unstructured":"Falchi L, Carlo-Stella C, Morschhauser F, et al. Glofitamab monotherapy in pts with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study. J Clin Oncol 41, 7550(2023), Vol 41, Number 16 suppl. doi:10.1200\/JCO.2023.41.16_suppl.7550.","DOI":"10.1200\/JCO.2023.41.16_suppl.7550"},{"issue":"14","key":"10.1053\/j.seminhematol.2025.12.002_bib0063","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2024027044","article-title":"Odronextamab monotherapy in R\/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study","volume":"145","author":"Topp","year":"2025","journal-title":"Blood"},{"issue":"17","key":"10.1053\/j.seminhematol.2025.12.002_bib0064","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.12.002_bib0065","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/bloodadvances.2024014903","article-title":"Safety and efficacy of glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0066","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0067","doi-asserted-by":"crossref","unstructured":"Westin J, Olszewski AJ, Fogliatto L, et al. SUNMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. J Clin Oncol 41, TPS7586(2023). Vol 41, Number 16 suppl. doi:10.1200\/JCO.2023.41.16_suppl.TPS7586.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7586"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0068","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1182\/blood-2023-174213","volume":"142","author":"Hutchings","year":"2023","journal-title":"Blood"},{"issue":"10466","key":"10.1053\/j.seminhematol.2025.12.002_bib0069","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"The Lancet"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.12.002_bib0070","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/blood.2024026830","article-title":"Epcoritamab plus GemOx in transplant-ineligible relapsed\/refractory DLBCL: results from the EPCORE NHL-2 trial","volume":"145","author":"Brody","year":"2025","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0071","doi-asserted-by":"crossref","unstructured":"Koh Y, Byun JM, Hong J, et al. Glofitamab combined with poseltinib and lenalidomide for relapsed\/refractory diffuse large B cell lymphoma: interim analysis of GPL study. J Clin Oncol 42, 7066(2024). Vol 42, Number 16 suppl. doi:10.1200\/JCO.2024.42.16_suppl.7066.","DOI":"10.1200\/JCO.2024.42.16_suppl.7066"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0072","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1182\/blood-2024-199301","article-title":"Fixed-duration Epcoritamab plus Lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL): updated results from arm 1 of the Epcore NHL-5 trial","volume":"144","author":"Gurion","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0073","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2023-174081","article-title":"Glofitamab plus R-CHOP induces high response rates with a manageable safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): a 12-month analysis from a phase ib study","volume":"142","author":"Topp","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0074","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2023-173953","volume":"142","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0075","doi-asserted-by":"crossref","unstructured":"Falchi L, Clausen M, Offner F, et al. Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B cell lymphoma, including double-hit\/triple-hit lymphoma: updated EPCORE NHL-2 data. J Clin Oncol 41, 7519(2023). Vol 41, Number 16 suppl. doi:10.1200\/JCO.2023.41.16_suppl.7519.","DOI":"10.1200\/JCO.2023.41.16_suppl.7519"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0076","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood-2023-180935","article-title":"Epcoritamab SC+ R-Mini-CHOP leads to high complete metabolic response rates in patients with previously untreated diffuse large B-cell lymphoma ineligible for full-dose R-CHOP: first disclosure from arm 8 of the EPCORE NHL-2 trial","volume":"142","author":"Vermaat","year":"2023","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.12.002_bib0077","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1182\/bloodadvances.2023010840","article-title":"Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study","volume":"7","author":"Olszewski","year":"2023","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0078","doi-asserted-by":"crossref","unstructured":"Dickinson M, Viardot A, Marks R, et al. Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): results from a phase IB study. J Clin Oncol 41, 7549(2023). Vol 41, Number 16 suppl. doi:10.1200\/JCO.2023.41.16_suppl.7549.","DOI":"10.1200\/JCO.2023.41.16_suppl.7549"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0079","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.1016\/S2152-2650(24)01527-1","article-title":"ABCL-417 first data from subcutaneous Epcoritamab+ Polatuzumab Vedotin Rituximab, Cyclophosphamide Doxorubicin, and Prednisone (Pola-RCHP) for first-line diffuse large B-cell lymphoma (DLBCL): EPCORE NHL-5","volume":"24","author":"Kerr","year":"2024","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0080","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2023-177588","article-title":"Mosunetuzumab and polatuzumab vedotin demonstrates preliminary efficacy in elderly unfit\/frail patients with previously untreated diffuse large B-cell lymphoma","volume":"142","author":"Olszewski","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.12.002_bib0081","doi-asserted-by":"crossref","first-page":"1718.1","DOI":"10.1182\/blood-2024-194000","article-title":"SKYGLO: a global phase III randomized study evaluating Glofitamab plus Polatuzumab Vedotin+ Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) versus Pola-R-CHP in previously untreated patients with large B-cell lymphoma (LBCL)","volume":"144","author":"Advani","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0082","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/hon.3166_OT28","article-title":"Phase 3 trial of subcutaneous epcoritamab+ r-chop versus r-chop in patients (PTS) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): Epcore Dlbcl-2","volume":"41","author":"Sehn","year":"2023","journal-title":"Hematologic Oncol"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0083","doi-asserted-by":"crossref","unstructured":"Matasar M, Turgut B, Tessoulin B, et al. Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3). J Clin Oncol 42, TPS7086(2024). Vol 42, Number 16 suppl. doi:10.1200\/JCO.2024.42.16_suppl.TPS7086.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7086"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0084","doi-asserted-by":"crossref","unstructured":"Kim TM, Yoon DH, Gaballa SR, et al. Safety and efficacy of AZD0486, a CD19xCD3 T-cell engager, in relapsed or refractory diffuse large B-cell lymphoma.J Clin Oncol 43, 7046(2025). Vol 43, Number 16 suppl. doi:10.1200\/JCO.2025.43.16_suppl.7046.","DOI":"10.1200\/JCO.2025.43.16_suppl.7046"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.12.002_bib0085","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0086","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2023-173946","article-title":"GLOBRYTE: a phase III, open-label, multicenter, randomized trial evaluating glofitamab monotherapy in patients with relapsed or refractory mantle cell lymphoma","volume":"142","author":"Phillips","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2025.12.002_bib0087","doi-asserted-by":"crossref","first-page":"3042.3","DOI":"10.1182\/blood-2024-209493","volume":"144","author":"Seshadri","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0088","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2024-197902","article-title":"Mosunetuzumab monotherapy demonstrates encouraging activity and a manageable safety profile in patients with heavily pre-treated relapsed or refractory mantle cell lymphoma","volume":"144","author":"Budde","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0089","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2023-174956","article-title":"Fixed duration mosunetuzumab plus polatuzumab vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed\/refractory mantle cell lymphoma: initial results from a phase ib\/II study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0090","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1182\/blood-2024-200770","article-title":"Trial in progress: odronextamab for the treatment of patients with relapsed\/refractory mantle cell lymphoma following prior BTK inhibitor therapy-a cohort of the ELM-2 study","volume":"144","author":"Cho","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0091","doi-asserted-by":"crossref","unstructured":"Eyre TA, Rhodes J, Cheah C, et al. SOUNDTRACK-E: a phase 1\/2, open-label, multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies. J Clin Oncol 43, TPS7083(2025). Vol 43, Number 16 suppl. doi:10.1200\/JCO.2025.43.16_suppl.TPS7083.","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7083"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0092","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2024-200190","article-title":"Efficacy and safety of Odronextamab in relapsed\/refractory marginal zone lymphoma (R\/R MZL): data from the R\/R MZL cohort in the ELM-2 study","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0093","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1182\/blood-2023-174292","article-title":"Early complete responses with mosunetuzumab monotherapy in treatment-na\u00efve follicular and marginal zone lymphomas with only low-grade cytokine release syndrome","volume":"142","author":"Lynch","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0094","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2024-193022","article-title":"Mosunetuzumab with response-driven lenalidomide augmentation as first-line therapy for symptomatic follicular or marginal zone lymphoma: interim analysis of a Multi-center phase 2 study","volume":"144","author":"Olszewski","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0095","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood-2023-180473","article-title":"Marsun, a phase III, multicenter, open label, randomized, controlled study investigating mosunetuzumab-lenalidomide versus investigator choices in patients with relapsed or refractory marginal zone lymphoma (R\/R MZL)","volume":"142","author":"Thieblemont","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0096","doi-asserted-by":"crossref","unstructured":"Vitolo U, Merli M, Norasetthada L, et al. Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed\/refractory (R\/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5). J Clin Oncol 42, TPS7094(2024). Vol 42, Number 16 suppl. doi:10.1200\/JCO.2024.42.16_suppl.TPS7094.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7094"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0097","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.12.002_bib0098","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-22-3667","article-title":"Dissecting the mechanisms underlying the cytokine release syndrome (CRS) mediated by T-cell bispecific antibodies","volume":"29","author":"Leclercq-Cohen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0099","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1190379","article-title":"Cytokine release syndrome and cancer immunotherapies\u2013historical challenges and promising futures","volume":"14","author":"Shah","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.12.002_bib0100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.12.002_bib0101","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell\u2013Engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"36","key":"10.1053\/j.seminhematol.2025.12.002_bib0102","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell\u2013engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7_Supplement","key":"10.1053\/j.seminhematol.2025.12.002_bib0103","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1158\/1538-7445.AM2023-2798","article-title":"Simplifying selection and optimization of step-up dosing of subcutaneous Epcoritamab to mitigate CRS risk using repeated time-to-event modeling","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0104","doi-asserted-by":"crossref","unstructured":"Bartlett NL, Sehn LH, Assouline SE, et al. Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 37, 7518(2019). Vol 37, Number 16 suppl. doi:10.1200\/JCO.2019.37.15_suppl.7518.","DOI":"10.1200\/JCO.2019.37.15_suppl.7518"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0105","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1182\/blood-2019-123712","article-title":"Population pharmacokinetics and novel exposure-response analyses to inform optimal biologic dose selection for CD20-TCB, a T-cell-engaging bispecific antibody, in relapsed or refractory B-cell non-hodgkin lymphoma","volume":"134","author":"Djebli","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0106","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41540-020-00145-7","article-title":"Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling","volume":"6","author":"Hosseini","year":"2020","journal-title":"NPJ Syst Biol Applic"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.12.002_bib0107","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/biom13020382","article-title":"Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.12.002_bib0108","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3324\/haematol.2024.286257","article-title":"Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed\/refractory large B-cell lymphoma","volume":"110","author":"Falchi","year":"2024","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.12.002_bib0109","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"New Engl J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.12.002_bib0110","first-page":"1","article-title":"Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma and exposure\u2013response in CLL","volume":"3","author":"Gibiansky","year":"2014","journal-title":"CPT: Pharmacometr Syst Pharmacol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.12.002_bib0111","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1188\/17.CJON.S2.29-34","article-title":"Cytokine release syndrome","volume":"21","author":"Smith","year":"2017","journal-title":"Clin J Oncol Nursing"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0112","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood-2024-194612","volume":"144","author":"Bartlett","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0113","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2083479","article-title":"Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors","volume":"11","author":"Leclercq","year":"2022","journal-title":"Oncoimmunology"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.12.002_bib0114","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-21-0470","article-title":"Cytokine release syndrome by T-cell\u2013redirecting therapies: can we predict and modulate patient risk?","volume":"27","author":"Van De Vyver","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1053\/j.seminhematol.2025.12.002_bib0115","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/bloodadvances.2023011089","article-title":"Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma","volume":"8","author":"Gritti","year":"2024","journal-title":"Blood Adv"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.12.002_bib0116","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0117","doi-asserted-by":"crossref","unstructured":"Kim DH, Kwon S, Cha S, et al. Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea. Therap Adv Hematol. doi:10.1177\/20406207251406461.","DOI":"10.1177\/20406207251406461"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0118","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/0008-5472.CAN-19-1131","article-title":"Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events","volume":"80","author":"Klinger","year":"2020","journal-title":"Cancer Res"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.12.002_bib0119","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.12.002_bib0120","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clml.2023.12.005","article-title":"Mosunetuzumab safety profile in patients with relapsed\/refractory B-cell non-hodgkin lymphoma: clinical management experience from a pivotal phase I\/II trial","volume":"24","author":"Matasar","year":"2024","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.12.002_bib0121","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1111\/cas.15996","article-title":"Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed\/refractory diffuse large B-cell lymphoma","volume":"114","author":"Izutsu","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0122","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2023-174415","article-title":"Incidence of infections associated with the use of bispecific antibodies in B-cell non-hodgkin lymphomas","volume":"142","author":"Fares","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0123","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2023-187911","article-title":"Infectious complications in patients with relapsed or refractory (R\/R) Non-Hodgkin's lymphoma (NHL) treated with the anti-CD20xCD3 bispecific antibody (BsAb) Mosunetuzumab","volume":"142","author":"Shahid","year":"2023","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.12.002_bib0124","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis","volume":"8","author":"Reynolds","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0125","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4143\/crt.2023.738","article-title":"Impact of T-cell engagers on COVID-19\u2013related mortality in B-cell lymphoma patients receiving B-cell depleting therapy","volume":"56","author":"Lee","year":"2024","journal-title":"Cancer Res Treatm"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0126","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.19156","article-title":"Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy","volume":"204","author":"Kyvsgaard","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0127","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev"},{"issue":"16","key":"10.1053\/j.seminhematol.2025.12.002_bib0128","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7 CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.12.002_bib0130","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008338","article-title":"Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20\u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory B-cell non-hodgkin lymphoma","volume":"12","author":"Brouwer-Visser","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.12.002_bib0131","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2023022348","article-title":"Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas","volume":"143","author":"Schuster","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0132","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood-2024-204772","article-title":"NOTCH1 Mutations are associated with therapy-resistance in patients with B-cell lymphoma treated with CD20xCD3 bispecific antibodies","volume":"144","author":"Kyvsgaard","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0133","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/leu.2015.182","article-title":"NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation","volume":"30","author":"Pozzo","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.12.002_bib0134","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.12.002_bib0135","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","article-title":"Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies","volume":"11","author":"van de Donk","year":"2024","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.12.002_bib0136","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.12.002_bib0137","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T-cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1085-0","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.12.002_bib0139","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.12.002_bib0140","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-12-3676","article-title":"Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance","volume":"19","author":"de Haart","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0141","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-021-01134-x","article-title":"Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.12.002_bib0142","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.2023021672","article-title":"Sequential antigen loss and branching evolution in lymphoma after CD19-and CD20-targeted T-cell\u2013redirecting therapy","volume":"143","author":"Duell","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.12.002_bib0143","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood.2023022682","article-title":"CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models","volume":"144","author":"Brinkmann","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.12.002_bib0144","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood-2007-08-110072","article-title":"Bispecific anti-CD20\/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action","volume":"111","author":"Qu","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0145","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2115213","article-title":"Development of T-cell engagers selective for cells co-expressing two antigens","volume":"14","author":"Dicara","year":"2022","journal-title":"MAbs"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.12.002_bib0146","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2022-168904","article-title":"PIT565, a first-in-class anti-CD19, anti-CD3, anti-CD2 trispecific antibody for the treatment of B cell malignancies","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0147","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.575737","article-title":"Combination of T-cell bispecific antibodies with PD-L1 checkpoint inhibition elicits superior anti-tumor activity","volume":"10","author":"Sam","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.12.002_bib0148","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-065X.2007.00570.x","article-title":"From T-cell activation signals to signaling control of anti-cancer immunity","volume":"220","author":"Cronin","year":"2007","journal-title":"Immunologic Rev"},{"issue":"670","key":"10.1053\/j.seminhematol.2025.12.002_bib0149","doi-asserted-by":"crossref","first-page":"eabn1082","DOI":"10.1126\/scitranslmed.abn1082","article-title":"CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models","volume":"14","author":"Wei","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.seminhematol.2025.12.002_bib0150","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2024-200096","article-title":"Englumafusp Alfa (CD19-4-1BBL) combined with Glofitamab is safe and efficacious in patients with r\/r B-NHL: extended follow up analysis of the dose-escalation part of phase 1 trial BP41072","volume":"144","author":"Hutchings","year":"2024","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T14:01:36Z","timestamp":1773496896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":150,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0037196325000563"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.12.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-cell engaging antibodies for B-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}